DSIPLongevity
Delta sleep-inducing peptide studied for sleep and stress.
- Status
- Research / not approved
- Developer
- Isolated 1977 by Schoenenberger & Monnier (University of Bern)
- Receptors / target
- No single established receptor or molecular target; mechanism poorly characterized
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- sleep regulationstress resiliencecircadian rhythmpain modulation
Overview
DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide first isolated in the 1970s by the Schoenenberger–Monnier group in Basel from the cerebral venous blood of rabbits whose brains had been electrically stimulated to induce sleep. It is named for its early association with delta-wave (slow-wave) sleep, but decades later its natural physiological role remains unconfirmed. DSIP is not an approved drug; it is sold only as a research chemical and is offered here strictly for research use, with no therapeutic or dosing claims.
Mechanism
DSIP has no single established molecular target — no validated DSIP receptor, and no confirmed DSIP gene or precursor protein, has ever been isolated, which is unusual for a peptide studied this long. Proposed actions span modulation of slow-wave sleep, the stress/HPA axis, and neuroendocrine output (including sleep-related growth-hormone release), but these remain hypotheses rather than mapped pathways. A 2006 review in the Journal of Neurochemistry explicitly calls DSIP a "still unresolved riddle" and notes the sleep hypothesis is weakly documented. The mechanism is genuinely poorly characterized.
Clinical evidence
Human evidence is old, small and mixed. An early double-blind crossover study in 6 healthy volunteers (1981) reported increased sleep after intravenous DSIP, but a later double-blind study in 16 chronic insomniacs (1992) found only weak effects and concluded that short-term DSIP "is not likely to be of major therapeutic benefit." A separate 1984 uncontrolled pilot in 7 chronic-pain patients reported pain reduction but had no control group. The clearest mechanistic support is animal work — e.g., a 1988 rat study in which anti-DSIP antiserum blocked rebound slow-wave sleep and sleep-related growth-hormone release — which cannot substitute for controlled human efficacy data.
Safety profile
The small early human trials reported good short-term tolerability with no notable adverse events, but that is reassuring only in the narrowest sense: the studies enrolled a handful of subjects, used short intravenous or subcutaneous exposures, and were run in the 1980s–early 1990s. There is no modern safety surveillance, no long-term or repeated-dose human data, and no purity or manufacturing oversight for the research-chemical product sold today. DSIP is not FDA-evaluated or approved for any use; research use only, and nothing here is medical or dosing advice.
- Same night / days
Marketed for sleep on a same-night basis, but the old, small human studies were mixed-to-negative and the mechanism is poorly characterized.
- Reality
No reliable modern time-course exists; effects are not established in humans.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Injection-site irritation
- Headache
- Transient dizziness or grogginess
- No well-characterized human adverse-event profile
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No human contraindication data exist for DSIP; the small early trials are not a basis for safety in any population.
- Avoid in pregnancy and breastfeeding — no reproductive or developmental safety data.
- Not for therapeutic use; research-chemical material is of unverified identity and purity.
- No documented human drug interactionsInteraction profile uncharacterized in humans (research use only)
Compare
- vs Selank
Another short neuropeptide marketed for calming/relaxation, though Selank targets anxiety rather than sleep and likewise lacks robust Western evidence.
FAQ
Does DSIP actually improve sleep?
The evidence is weak. The human studies are old, small and mixed-to-negative: an early 6-subject crossover suggested benefit, but a later double-blind study in 16 chronic insomniacs found only weak effects and concluded short-term DSIP is unlikely to be of major therapeutic benefit. No reliable modern data establish a sleep effect.
How does DSIP work?
Honestly, no one knows. DSIP has no validated receptor, gene or precursor protein, and a 2006 review called it a still-unresolved riddle. Proposed actions on slow-wave sleep and the stress axis remain hypotheses, not mapped pathways.
Is DSIP approved or safe to use?
No. DSIP is not FDA-evaluated or approved for any use and is sold only as a research chemical. There is no modern safety surveillance, no long-term human data and no purity oversight for the material sold today. Research use only.
How was DSIP given in the studies?
The early human studies used intravenous or subcutaneous injection — not an oral tablet or a nasal spray. DSIP is a peptide and would be broken down in the gut, so the historical research routes are parenteral. There is no validated route, dose or formulation for any modern use.
What is DSIP's half-life?
Very short. Early studies reported it was cleared from plasma within minutes, but a reliable modern pharmacokinetic figure has never been established. The brevity of any plasma presence is one reason its proposed central effects are hard to explain or reproduce.
Is DSIP banned in sport?
DSIP is not specifically named on the WADA Prohibited List, but absence from the list is not a clearance — novel peptides can fall under WADA catch-all provisions for non-approved substances, and an unapproved research chemical of unverified contents carries its own contamination risk for tested athletes.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.